NCT02763046View on ClinicalTrials.gov

Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis

PHASE4CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

September 24, 2019

Study Completion Date

September 24, 2019

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Secukinumab (AIN457) 150 mg s.c.

Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 4 x 150 mg secukinumab s.c. every 4 weeks Delayed NSAID tapering (tapering following 4 weeks of secukinumab treatment).

DRUG

Secukinumab (AIN457) 150 mg s.c.

Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 3 x 150 mg secukinumab s.c. every 4 weeks Early NSAID tapering (tapering at the start of secukinumab treatment).

DRUG

Placebo - Secukinumab (AIN457) 150 mg s.c.

Placebo for 15 weeks. From Week 16 on, 5 x 150 mg secukinumab s.c. weekly.

Trial Locations (39)

12161

Novartis Investigative Site, Berlin

12163

Novartis Investigative Site, Berlin

13055

Novartis Investigative Site, Berlin

13125

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

14059

Novartis Investigative Site, Berlin

18209

Novartis Investigative Site, Bad Doberan

19055

Novartis Investigative Site, Schwerin

22081

Novartis Investigative Site, Hamburg

22143

Novartis Investigative Site, Hamburg

22415

Novartis Investigative Site, Hamburg

23538

Novartis Investigative Site, Lübeck

24768

Novartis Investigative Site, Rendsburg

25335

Novartis Investigative Site, Elmshorn

31582

Novartis Investigative Site, Nienburg

37075

Novartis Investigative Site, Göttingen

39104

Novartis Investigative Site, Magdeburg

39110

Novartis Investigative Site, Magdeburg

44649

Novartis Investigative Site, Herne

48324

Novartis Investigative Site, Sendenhorst

51149

Novartis Investigative Site, Cologne

54292

Novartis Investigative Site, Trier

60528

Novartis Investigative Site, Frankfurt am Main

66111

Novartis Investigative Site, Saarbrücken

66346

Novartis Investigative Site, Püttlingen

69120

Novartis Investigative Site, Heidelberg

79106

Novartis Investigative Site, Freiburg im Breisgau

80331

Novartis Investigative Site, München

81541

Novartis Investigative Site, München

81675

Novartis Investigative Site, München

90443

Novartis Investigative Site, Nuremberg

91056

Novartis Investigative Site, Erlangen

95444

Novartis Investigative Site, Bayreuth

09130

Novartis Investigative Site, Chemnitz

03042

Novartis Investigative Site, Cottbus

01307

Novartis Investigative Site, Dresden

09599

Novartis Investigative Site, Freiberg

04103

Novartis Investigative Site, Leipzig

04109

Novartis Investigative Site, Leipzig

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY